CDK6 is highly expressed in AML patient samples and represents a promising target in MLL fusion-expressing, FLT3-ITD-positive and NUP98 fusion protein-driven AML [42, 43]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.